Baricitinib Provides Sustained, Long-Term Efficacy With Consistent Safety for Up to 5 Years of Treatment in Adults With Severe Alopecia Areata: Final Results From BRAVE-AA1 and BRAVE-AA2

    November 2025 in “ SKIN The Journal of Cutaneous Medicine ”
    Ruth Ann Vleugels, Bianca Maria Piraccini, Natasha Atanaskova Mesinkovska, Arash Mostaghimi, Yutaka Shimomura, Angelina Sontag, Fionn McSwiney, Hitendra Pandey, Karen Denning, Brett King
    TLDR Baricitinib is effective and safe for treating severe alopecia areata for up to 5 years.
    The study titled "Baricitinib Provides Sustained, Long-Term Efficacy With Consistent Safety for Up to 5 Years of Treatment in Adults With Severe Alopecia Areata" presents the final results from the BRAVE-AA1 and BRAVE-AA2 trials. It demonstrates that Baricitinib, a medication, offers sustained efficacy and consistent safety for up to 5 years in treating adults with severe alopecia areata. This conclusion is based on long-term data, highlighting the potential of Baricitinib as a viable treatment option for this condition. The study emphasizes the importance of long-term treatment options for individuals suffering from severe alopecia areata.
    Discuss this study in the Community →

    Research cited in this study

    3 / 3 results